3ZHOU Hai-jun(周海均)．Technical Requirements for Registration of Pharmaceuticals for Human Use-Quality(药品注册的国际技术要求-质量部分)．Beijing(北京)：People’s Medical Publishing House(人民卫生出版社)，2000．143.
4WANG Jun-zhi(王军志)．Research，Development and Quality Control of Biopharmaceuticals(生物技术药物研究开发和质量控制)．Beijing(北京)：Science Press(科学出版社)，2002．154.
5Masci P P,Whitaker A N,Sparrow L G,et al. Textilinins from Pseudonaja textilis textilis. Characterization of two plasmin inhibitors that reduce bleeding in an animal model[J]. Blood Coagul. Fibrinolysis, 2000,11 :385-393.
6Millers E K, Masci P P, Lavin M F, et al. Crystallization and preliminary X-ray analysis of a Kunitz-type inhibitor, textilinin- 1 from Pseudonaja textilis textilis[J].Acta Crystallogr. F: Structural Biology and Crystallization Communications, 2006, 62:642-645.
7Flight S M,Johnson L A,Du Q S,et al. Textilinin-1 ,an alterna- tive anti-bleeding agent to aprotinin:Importance of plasmin in- hibition in controlling blood loss[J]. Br. J. Haematol, 2009, 145:207-211.
8Flight S,Johnson L, Trabi M, et al. Comparison of Textilinin-1 with Aprotinin as Serine Protease Inhibitors and as Antifibrino- lyric Agents[J].Pathophysiol Haemos Thromb, 2005,34 : 188- 193.
9Hardy J F,Belisle S. Natural and synthetic antifibrinolytics in adult cardiac surgery:Efficacy and effectiveness[J].Can. J. An- aesth,1994,41 : 1104-1112.
10Pugh S C, Wielogorski A K. Acomparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and ho- mologous blood usage in patients underging cardiac surgery[J]. J Cardiothor Vasc Anes, 1995,9 : 240-244.
